We provide an overview of recent publications that extend clinically relevant knowledge relating to metformin's effects on lipids and atherosclerotic vascular disease and/or provide insights into the drug's mechanisms of action on the heart and vasculature.
INTRODUCTION
The biguanide metformin has been used for over 60 years as the first-line oral agent for glucose lowering in Type 2 diabetes (T2D) [1] . Metformin also retards progression from prediabetes to T2D [2] and, as shown by the UK Prospective Diabetes Study (UKPDS), reduces cardiovascular disease (CVD) events and mortality in T2D [3, 4] . Metformin lowers glucose by reducing glucose absorption from the gut and inhibiting hepatic glucose output [1] . In prediabetes and T2D metformin improves beta cell function and improves clustered metabolic risk factors [5] . Unlike most glucose control agents, metformin induces visceral fat loss and reduces waist circumference [6] . Metformin is quite frequently used offlabel as an insulin-sparing glucose control agent in overweight/obese people with Type 1 diabetes (T1D), though this is based on relatively small short-duration studies [7] .
Metformin's beneficial effects have been postulated to extend beyond glycaemia, to effects on multiple other pathways mediating complications, including lipoproteins, inflammation, thrombosis and oxidative stress ('pleiotropic' effects) [1, 8] . Metformin is low cost with an excellent safety profile, other than appreciable rates of gastrointestinal upset [1] , which can be reduced with meal-time dosing and extended release preparations [8] . Metformin reduces Vitamin B12 absorption, which may increase homocysteine levels but is currently thought to have only marginal clinical relevance in terms of neuropathy risk [9] . Lactic acidosis is a rare side-effect, the risk of which is increased with renal impairment [1] , hence recommendations to avoid use in late-stage CKD [10, 11] . Pleiotropic effects and mechanisms of action of metformin are still being identified: recent studies are reviewed herein.
Metformin is, therefore, a candidate for more widespread clinical use, particularly in an aging and obese population. Recent publications report surrogate measures of vascular disease in randomized controlled trials (RCTs) of metformin in T1D, prediabetes and T2D. Other articles report effects on novel vascular risk factors and provide insights into metformin's cellular actions.
METFORMIN'S CARDIOMETABOLIC EFFECTS IN TYPE 1 DIABETES
Interest in metformin as an insulin adjunct in T1D has arisen because of the benefits and challenges of optimizing glycaemia [12] and an increased rate of adiposity, which is associated with increased vascular complications [13, 14] . In the 2000s, a series of small short-term trials of metformin reported modest benefits for weight, insulin dose and LDL-cholesterol (LDL-C); meta-analyses confirmed a significant reduction in insulin dose requirement (6.6 IU/day, P < 0.001) with metformin, and weight reduction in some trials [7, 15] . Although there was no consistent evidence for HbA1c reduction, the UK National Institute for Health and Care Excellence (NICE) and the American Diabetes Association (ADA) recommended metformin for overweight/ obese T1D patients for improving glycaemia while limiting insulin dose [15, 16] . Subsequently in 140 overweight/obese adolescents with high HbA1c and insulin doses, 26 weeks of metformin treatment induced only a small (transient) reduction in HbA1c, and small reductions in BMI and insulin dose, with no change in lipids. No vascular measurements were made in this trial. [17] The REversing with MetfOrmin Vascular Adverse Lesions (REMOVAL) Trial addressed cardiometabolic health in T1D adults at high CVD risk [18, 19 && ,20
REMOVAL is the largest and longest trial of metformin in T1D and the first to evaluate a CVD end-point, albeit a surrogate measure of carotid-intima media thickness (cIMT). REMOVAL also included a vascular reactivity substudy. In this multicentre international RCT, 428 adults aged at least 40 years, with at least 5-years T1D and at least 3 of 10 CVD risk factors were randomized to placebo or metformin (1000 mg b.i.d. or lower if not tolerated) with insulin titrated towards HbA1c 7% (53 mmol/mol) [18,19 && ]. Participants were followed for a mean of 3 years with annual assessments of cIMT, vascular reactivity, renal and retinal status, CVD risk factors and side-effects [18, 19 && ]. cIMT was chosen as a surrogate CVD measure for several reasons: the need for a shorter smaller clinical trial than that required by clinical vascular end-point studies; because cIMT predicts CVD in the general population [22] ; and because in the (T1D) Diabetes Control and Complications Trial (DCCT) intensive management reduced cIMT [23] , which over 30 years follow-up was associated with better CVD outcomes [12] . cIMT is increased even in children with T1D [24] . REMOVAL participants had a mean age of 55 years, with 33 years T1D, blood pressure 130/ 72 mmHg, LDL-C 2.1 mmol/l. BMI indicated overweight/obesity in 71% whilst 82% were on statins, 73% were on antihypertension agents, and 39% were on antiplatelet agents [19 && ]. Relative to placebo the primary end-point of mean far wall cIMT (as per the Mannheim consensus, which excludes IMT measures >1.5 mm and plaque) was not significantly reduced. However, maximal cIMT (tertiary end-point), which includes plaque, was reduced by metformin (À0.01 mm, P ¼ 0.0093) [19 && ]. Vascular reactivity and (retinal photo-based) retinopathy progression did not differ between treatment arms. Renal function, assessed by estimated glomerular filtration rate (eGFR) increased (mean 4 ml/min/1.73 m 2 ) soon after
KEY POINTS
Metformin has been in clinical use for glucose control in T2D for over 60 years and has proven effects in reducing progression from prediabetes to T2D and in reducing rates of cardiovascular disease (CVD) events and death in T2D. These actions occur in part via glucose lowering, and in part via other 'pleiotropic' effects.
Other than the recent REMOVAL trial, very few clinical trials have studied the effect of metformin on vascular complications in T1D.
Understanding of the mechanisms of metformin's apparently protective effects on vascular cells is gradually accumulating, including effects related to AMPK, scavenger receptors, hTERT, DNA methylation and mitochondrial biogenesis.
Surrogate end-point trials in high-CVD risk adults (carotid-intima media thickness) and in young people (vascular reactivity) with T1D support beneficial actions of metformin on the vasculature. These results highlight the need for CVD outcome trials.
In clinical studies of prediabetes and T2D, metformin has favourable effects including reduction of vascular calcification and novel vascular risk factors.
metformin commencement then declined in parallel with the placebo group, resulting in apparently better renal function with metformin [19 && ]. Further renal measures are being assessed, but interestingly a similar trend (of borderline statistical significance) was recently observed in a 1 year pilot feasibility study for a planned cardiovascular outcome trial with metformin in prediabetes [the Glucose Lowering In Nondiabetic hyperglycaemia Trial (GLINT)] [25] . Metformin was associated with a transient 0.24% (2.6 mmol/mol) HbA1c reduction, with no difference in severe hypoglycaemia or diabetic ketoacidosis (DKA) rates [19 && ]. Metformin allocation was associated with sustained small weight loss (1.17 kg), LDL-C reduction (0.13 mmol/l) and a 2 IU/ day reduction in insulin dose. Relative to placebo, about double the number of participants allocated metformin discontinued treatment; mean metformin dosage was 1.4 g/day, with high rates of gastrointestinal upset, and a higher rate (12 vs. 5%) of Vitamin B12 deficiency. There were only three CVD (of seven) deaths, two with metformin and one with placebo [19 && ]. Overall, the results were in keeping with nonglucose-mediated atheroprotective effects of metformin in T1D and supported the need for CVD event end-point studies.
Metformin improves vascular function in youth with Type 1 diabetes
Vascular reactivity, such as ultrasound measured brachial artery dilatation [flow mediated dilatation (FMD) and/or by glyceryl trinitrate (GTN)], is associated with and predictive of CVD [26] and coronary artery calcification (CAC) [27] , and is abnormal in T2D [28] and T1D [29] . Changes in FMD-induced and GTN-induced reactivity can be discordant, as FMD is dependent on nitric oxide (NO) released from endothelium whereas GTN, a NO donor, directly affects vascular smooth muscle and is, therefore, endothelium independent [30] .
In a single paediatric centre experienced in FMDmediated and GTN-mediated vascular reactivity (coefficients of variations 4%), a 1-year doubleblind placebo-controlled trial of metformin (with weight appropriate doses up to 1000 mg b.i.d.) was conducted in 90 youth aged 8-18 years, at least 6-months T1D and above average weight (BMI >50th percentile) [31 && ]. Youth on or with a contraindication to metformin, or on statins, blood pressure drugs or multivitamins, or with recent severe hypoglycaemia, DKA, or serious comorbidities were excluded. Vascular reactivity was measured at baseline, 3, 6 and 12 months. Whilst the primary end-point, FMD, was unchanged, metformin improved GTN-induced reactivity (3.3%, P ¼ 0.03) independent of improved HbA1c. As expected, given the short duration, there were no changes in carotid or aortic IMT. Metformin reduced HbA1c (1%, P ¼ 0.001), with greater benefit at 3 months, when adherence was greater, and lowered insulin doses, and leptin over 12 months. BMI, body composition, blood pressure, renal function, lipids, homocysteine, C-reactive protein (CRP) and adiponectin did not change significantly [31 && ]. Ten patients discontinued treatment (six on metformin) and mean tablet adherence was 75%, similar in both study arms. Lactate levels did not change and there were no episodes of lactic acidosis, severe hypoglycaemia or DKA. Metformin slightly reduced Vitamin B12, though levels were still within normal range, and homocysteine did not rise [31 && ]. FMD results were negative in this paediatric cohort [31 && ], as was the reactive hyperaemia index in the REMOVAL Study [19 && ], but GTN-induced hyperaemia was improved by metformin in T1D youth [31 && ]. Important study differences include the methodology of assessment (GTN was not used in REMOVAL), and participant demographics, including age, T1D duration, complications and medications. The positive (albeit nonprimary) end points in both studies provide clinicians with additional evidence of a potential vascular benefit of adjunct metformin therapy in T1D. These data are corroborated by recent studies in the STZ-diabetic mouse model in which metformin improved endothelial function and increased bone marrow-derived endothelial progenitor cells (EPCs) [32] , with clinical confirmation of the latter in the T1D MERIT study [33] .
Surrogate endpoint data from recent trials, therefore, support the need for clinical CVD endpoint trials with metformin in T1D. The likelihood of such trials being funded either by research charities, governmental agencies or pharmaceutical companies currently seems low, given that thousands of patients would need to be randomized over several years of follow-up and metformin has long been available in generic form.
METFORMIN VASCULAR EFFECTS IN PREDIABETES AND TYPE 2 DIABETES
As mentioned above, a beneficial effect of metformin on CVD outcomes in people with T2D is often considered quite established, on the basis of the UKPDS [3, 4] in 1998 and also (in insulin-treated patients) the HOME study (n ¼ 390) in 2009 in which the hazard ratio for reduction of CVD events over 4.3 years of follow-up was 0.61 [95% confidence intervals (CI) 0.40-0.94, P ¼ 0.02] [34] . However, when all available data are subjected to metaanalysis, some uncertainty remains [35 & ]. One recent small but interesting clinical trial (based on surrogate measures) aimed to examine some of the relevant mechanisms and gain insights into 'firstline' use of metformin as opposed to other agents in T2D.
The Sapporo Athero-Incretin Study 3 in T2D patients on 500-750 mg/day metformin evaluated if doubling the dose of metformin or adding a DPP-4 inhibitor (vildagliptin), which has glucose lowering, anti-inflammatory and antiatherosclerotic actions, improved brachial artery FMD (primary end point) and novel vascular risk factors [36] . The study randomized 97 patients with T2D [mean (SD), age 58.7 (11.0) years, HbA1c 7.5 (0.3)%] to vildagliptin or higher dose metformin for 12 weeks. There was no significant FMD change in either group. Metformin/ vildagliptin lowered HbA1c more [À0.80 (0.38) vs. À0.40 (0.47)%; P < 0.01] than high-dose metformin. Reductions in ApoB/A1 were significant, but similar with both treatments [36] . Thus, whilst combination therapy was effective in terms of glycaemia, no differences in effects on vascular or lipid parameters could be discerned between the two strategies.
In people without diabetes, the effect of metformin on CVD is much less certain. For example, in the double-blind, placebo-controlled Carotid Atherosclerosis MEtformin for Insulin ResistAnce Study (CAMERA) trial in people with established CVD but without diabetes, metformin treatment for 18 months had no effect on progression of mean cIMT (the primary end-point) or on total cholesterol, HDL-cholesterol, non-HDL-cholesterol, or triglycerides [37] . However, data suggesting an effect of metformin on vascular calcification in dysglycaemic patients have been reported [38
The Diabetes Prevention Program (DPP) is the longest (1996-2001) and largest (n ¼ 3234) trial of lifestyle or metformin for T2D prevention in adults with prediabetes and is in follow-up (DPP/Diabetes Prevention Program Outcomes Study (DPPOS), with an emphasis on cardiometabolic outcomes, cancer and long-term safety. An excellent review of the DPP/DPPOS was published in 2017 [40] . In brief, the DPP demonstrated that relative to placebo, over a mean 3.2 years follow-up, metformin 850 mg b.i.d. reduced progression to T2D by 31%, with greater benefit in the obese and in women with prior gestational diabetes. Intensive lifestyle reduced progression by 58%. Ten and 15-year follow-up (DPPOS) demonstrated 18% T2D reduction with metformin. HbA1c, fasting glucose, hepatic glucose output, beta cell function and insulin/proinsulin improved significantly. Most benefit (64%) was explained by weight reduction and decreased central adiposity (DPP) [38 && ,40] . Metformin did not improve lipid (triglycerides, LDL-C or HDL-C) levels or blood pressure, but improved CRP and tissue plasminogen activator (tPA) levels [40] . To date no reductions in microvascular complications have been reported and CVD events are still being monitored [40] .
In a DPP/DPPOS substudy (n ¼ 2029) a mean 14-years postrandomization, CAC was quantified in men (mean age 67 years) and women (mean age 63 years) [38 && ]. T2D had developed in 54, 51 and 59% of the metformin, lifestyle and placebo groups, respectively. Relative to placebo, metformin [for 9.6 (9.4) years] was associated with lower presence of CAC (i.e. CAC score above zero; 75 vs. 84%, P ¼ 0.02) and severity (39.5 vs. 66.9 Agatson units, P ¼ 0.04) in men only. This metformin benefit was independent of age, BMI, progression to diabetes or statin use [38 && ]. Long-term safety and tolerability was good, with (predominantly gastrointestinal) side-effects in 9.8% of metformin-allocated patients (vs. 1.1% placebo) and lower Vitamin B12, but no lactic acidosis with greater than 15 000 patient years of metformin [40] . Rates of clinical CVD events from the ongoing follow-up study are awaited.
Calcium scores in peripheral vascular disease
In a cross-sectional study of 198 people with T2D those on metformin (81%) had a 41% lower prevalence of below knee vascular calcification and lower serum interleukin-6 (IL-6) levels than nonmetformin users (independent of age, diabetes duration, sex, smoking, lipids, HbA1c, eGFR, prior CVD, retinopathy, neuropathy, insulin and IL-6 levels) [39 & ]. This observation is supported by lower rates of lower limb amputation rates in T2D patients treated with metformin vs. sulfonylurea or insulin monotherapy [41] .
These two studies suggest that metformin may protect against vascular calcification in dysglycaemia. Potential mechanisms include anti-inflammatory, antioxidant and specific anticalcification effects, which may relate to AMPK activation [1, 8, 42, 43] .
We believe that there is sufficient evidence to support the commissioning of a cardiovascular endpoint trial of metformin in people without diabetes and have recently contributed to a feasibility trial (GLINT) [25] . If commissioned, this will provide more definitive evidence of metformin's effects on CVD and the results will have implications for people with and without diabetes (whether T1D or T2D).
METFORMIN EFFECTS ON NOVEL VASCULAR RISK FACTORS

Glucagon-like peptide-1
Mechanism(s) of metformin delaying glucose uptake from the gut have not been fully elucidated.
Glucagon-like peptide-1 (GLP-1) receptor agonist trial data in T2D support CVD safety and in some cases efficacy against CVD, with further evidence awaited [44] . In a substudy (n ¼ 173) of the above-mentioned CAMERA trial of patients without diabetes metformin sustainably (at least 18 months) increased (%23%) total GLP-1 levels, independent of changes in glycaemia or weight but did not reduce cIMT [37] . This is the Newly documented effects with potential vascular effects are in italics and underlined Documented effects reported herein are in italics and underlined. Levels of evidence for clinical studies: I, evidence from a systematic review of Level II studies; II, evidence from a RCT; III-1, evidence from a pseudo-RCT; III-2, evidence from a comparative study with concurrent controls (such as a cohort study, case-control study, interrupted time series with a control group); III-3, evidence from a comparative study without concurrent controls (such as a historical control study, two or more single-arm studies, or interrupted time series without a parallel control group).
largest and longest metformin study evaluating GLP-1. In a DIRECT consortium (n ¼ 775 T2D patients) study metformin use was associated with 14.1% higher total GLP-1 and 39.1% higher fasting active GLP-1, independent of HbA1c, weight or sex, but postprandial levels did not differ from other therapies [45] . These exploratory studies support a role for the incretin axis as a component of the mechanism of metformin's cardiometabolic effects.
Neutrophil gelatinase-associated lipocalin
In an observational study, circulating neutrophilderived acute phase protein was measured in 67 T2D and 69 nondiabetic participants and also in their carotid endarterectomy samples (mRNA expression) [46 & ]. Relative to nondiabetic control samples, circulating neutrophil gelatinase-associated lipocalin (NGAL) levels were greater than 50% higher in T2D, and significantly higher in those with carotid artery stenosis (CAS), whether symptomatic or asymptomatic. NGAL mRNA was present in 95% of T2D endarterectomy tissues vs. 5% from nondiabetic individuals (P < 0.0001). Those (n ¼ 17) who were prescribed metformin had lower NGAL (60.7 vs. 121.7 ng/ml, P < 0.0001) and carotid tissues from these individuals had less leukocyte infiltration and fewer more complex and vulnerable plaques [46 & ].
Metformin effects in vascular cells
Uptake of lipids, including oxidized LDL (Ox-LDL) by macrophages and their subsequent apoptosis are key steps in atherosclerosis; there is evidence that metformin can inhibit both of these. In human THP-1 cells, a monocyte-like cell line, it was demonstrated that metformin can attenuate: Ox-LDL uptake by reducing scavenger receptor (SRA and CD36) expression by suppression of b-catenin, activating protein-1 and PPAR-g; Ox-LDL-induced endoplasmic reticulum stress and reactive oxygen species generation, and Ox-LDL-induced mitochondrial membrane depolarization and cyto-C release [ 
CONCLUSION
Recent studies reveal new knowledge of an old drug's cardiometabolic effects, supporting the case for cardiovascular outcome trials in individuals with T1D and nondiabetic dysglycaemia. At the same time, molecular and cellular studies are providing insights into the mechanisms of metformin's actions on the vasculature, suggesting novel biomarkers that require validation in independent cohorts. These studies may guide development and targeting of novel agents for the treatment and prevention of cardiovascular and metabolic disease. Comprehensive series of studies in both a human monocyte cell line and cultured monocytes/macrophages from Type 2 diabetes patients delineating mechanisms of metformin's effects on AMPK and pro-inflammatory cylophilin A, with inhibition of Ox-LDL uptake and adverse cellular responses related to inflammation and oxidative stress. Results extend prior knowledge and point to additional targets as surrogate end-points and therapeutic targets to retard CVD. 50.
